WuXi Biologics (Cayman) Inc
HKEX:2269

Watchlist Manager
WuXi Biologics (Cayman) Inc Logo
WuXi Biologics (Cayman) Inc
HKEX:2269
Watchlist
Price: 17.46 HKD 0.46% Market Closed
Market Cap: 72.5B HKD
Have any thoughts about
WuXi Biologics (Cayman) Inc?
Write Note
WuXi Biologics (Cayman) Inc
/
Cash Flow Statement
/
Cash from Operating Activities

WuXi Biologics (Cayman) Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi Biologics (Cayman) Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash from Operating Activities
¥3.2B
CAGR 3-Years
13%
CAGR 5-Years
30%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash from Operating Activities
¥11.4B
CAGR 3-Years
34%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash from Operating Activities
¥2.5B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash from Operating Activities
¥1.1B
CAGR 3-Years
-4%
CAGR 5-Years
15%
CAGR 10-Years
37%
M
MGI Tech Co Ltd
SSE:688114
Cash from Operating Activities
-¥870.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Cash from Operating Activities
¥332.8m
CAGR 3-Years
262%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi Biologics (Cayman) Inc
Glance View

Market Cap
72.5B HKD
Industry
Life Sciences Tools & Services

WuXi Biologics (Cayman) Inc. emerged from the bustling arena of global pharmaceuticals as a beacon of innovation and flexibility in the biologics manufacturing space. Founded in 2010, this Chinese firm quickly established itself as a key player by offering a comprehensive suite of services that span the entire biologics development process. The company's strategy revolves around its "Follow-the-Molecule" business model, characterized by a symbiotic partnership with clients from the early stages of drug discovery through clinical development and all the way to commercial manufacturing. This approach ensures not only seamless integration across different development stages but also cultivates long-term relationships with clients, including startups and large pharmaceutical giants. Utilizing state-of-the-art technologies and an expansive network of manufacturing facilities around the globe, WuXi Biologics has positioned itself as an indispensable partner for firms looking to bring new biologics to market swiftly and efficiently. The revenue model of WuXi Biologics hinges on its ability to offer flexible, customer-centric solutions in a highly demanding industry. Unlike traditional pharmaceutical companies that solely profit from drug sales, WuXi Biologics earns money by leveraging its Contract Development and Manufacturing Organization (CDMO) platform to provide end-to-end services. This includes process development, clinical trials, regulatory submissions, and commercial production. The company capitalizes on strategic partnerships and its burgeoning pipeline of projects, earning fees at each stage of the drug development cycle. By ensuring proprietary access to its advanced technologies and broad capabilities, WuXi Biologics not only supports its clients' needs but also fortifies its revenue streams via milestone payments, service fees, and long-term manufacturing contracts. Such a business model not only diversifies its income but also mitigates risks associated with drug development uncertainty, allowing the company to thrive in the competitive global healthcare market.

Intrinsic Value
32.48 HKD
Undervaluation 46%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is WuXi Biologics (Cayman) Inc's Cash from Operating Activities?
Cash from Operating Activities
3.2B CNY

Based on the financial report for Jun 30, 2024, WuXi Biologics (Cayman) Inc's Cash from Operating Activities amounts to 3.2B CNY.

What is WuXi Biologics (Cayman) Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
30%

Over the last year, the Cash from Operating Activities growth was -53%. The average annual Cash from Operating Activities growth rates for WuXi Biologics (Cayman) Inc have been 13% over the past three years , 30% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.